Ultragenyx, Kyowa Hakko Kirin deal

Kyowa partnered with Ultragenyx to co-develop and co-commercialize KRN23, which is in development for X-linked hypophosphatemia (XLH). Ultragenyx will lead development for KRN23 and the partners will share costs in the U.S., Canada and EU. The companies will co-commercialize KRN23 in the U.S. and Canada, and Kyowa will commercialize the compound in the EU. Ultragenyx will be solely responsible for development and commercialization in Mexico and Central and South America, and Kyowa will retain rights to KRN23 elsewhere. The companies declined to provide financial details. ...